Germ-cell tumors (GCTs) are the most common malignancy in young men. There is a paucity of data on GCTs in developing countries. LACOG 0515 study aimed to evaluate clinical characteristics and treatment outcomes in patients with GCTs from Brazilian cancer centers.
This is a retrospective cohort study evaluating male patients diagnosed with GCTs from 2000 to 2018 in 13 Brazilian hospitals. We described baseline characteristics, progression-free survival (PFS), and overall survival (OS).
A total of 1232 patients were included, with a median age of 30 years. Histology was seminoma in 47.1% and non-seminoma GCT (NSGCT) in 52.9%. The primary tumor site was testis in 96.5%. At diagnosis, clinical stage I was present in 68.1% and 34.7% and clinical stages IS/II/III in 31.9% and 65.2% of patients with seminoma and NSCGT, respectively. Following orchiectomy, 55.2% of patients with clinical stage I were managed with surveillance. The 5-year disease-free survival rates among patients with stage I were 98.0% in seminoma and 92.3% in NSGCT, with 5-year OS of 99.6% and 97.6%, respectively. Among patients with advanced disease (IS, II, and III), the 5-year PFS were 88.7% in seminoma and 68.7% in NSGCT, with 5y-OS of 97.6% and 82.8%, respectively.
This is the largest Brazilian cohort of GCTs. Our results show a high rate of adjuvant chemotherapy in patients with clinical stage I. Although our data demonstrate slightly inferior PFS compared with the International Germ Cell Cancer Collaborative Group and other contemporary series, the OS rates were similar.
Clinical genitourinary cancer. 2022 Nov 12 [Epub ahead of print]
Diogo A Bastos, Aline Bobato Lara Gongora, Carlos Dzik, Denis Leonardo Jardim, Marina Piva, Flavio Mavignier Carcano, Glaucio Bertollo, Karine Trindade, Mariane Sousa Fontes, Andrey Soares, Tomas Reinert, Rita De Cassia Costamilan, Rodrigo Ughini Villarroel, Gabriel Watarai, Antonia Angeli Gazola, Daniel D Almeida Preto, Haila Mutti, Marcela Bonalumi Dos Santos, Rodrigo Coutinho Mariano, Monique Binotto, Monique Maciel Carvalho, Veronica Patrícia da Costa Oliveira, Rafaela Gomes, Taiane F Rebelatto, Fabio A Schutz, Oren Smaletz, Andre P Fay
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Hospital Sírio-Libanês, São Paulo, Brazil. Electronic address: ., Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Hospital Sírio-Libanês, São Paulo, Brazil., Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil., Hospital Amaral Carvalho, Jaú, Brazil., Barretos Cancer Hospital, Barretos, Brazil., AFECC - Hospital Santa Rita, Vitória, Brazil., Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Oncocentro, Fortaleza, Brazil., Grupo Oncoclínicas Botafogo, Rio de Janeiro, Brazil., Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil; Centro Paulista de Oncologia/Oncoclínicas- São Paulo, São Paulo, Brazil., Centro de Pesquisa da Serra Gaúcha (CEPESG), Caxias Do Sul, Brazil., IPCEM/UCS - Fundação Universidade de Caxias do Sul - Hospital Geral, Caxias do Sul, Brazil., Hospital São Vicente de Paulo, Passo Fundo, Brazil., Hospital São Lucas PUC-RS, Porto Alegre, Brazil; PUC-RS School of Medicine, Porto Alegre, Brazil., Hospital Israelita Albert Einstein, São Paulo, Brazil., Centro Paulista de Oncologia/Oncoclínicas- São Paulo, São Paulo, Brazil., Beneficência Portuguesa de São Paulo, São Paulo, Brazil., Oncocentro, Fortaleza, Brazil., Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Hospital São Lucas PUC-RS, Porto Alegre, Brazil; PUC-RS School of Medicine, Porto Alegre, Brazil.
PubMed http://www.ncbi.nlm.nih.gov/pubmed/36509612